The Impact of MTM Model on the Efficacy and Safety of Anticoagulant Therapy in Postoperative Colorectal Cancer Patients

What this Trial Is About

Researchers are studying the impact of the Medication Therapy Management (MTM) model on the safety and effectiveness of anticoagulant therapy in patients who have undergone surgery for colorectal cancer (CRC). These patients often face a high risk of recurrent venous thromboembolism (VTE) and bleeding events due to anticoagulant use. The study aims to reduce adverse drug events by improving management of anticoagulant therapy through pharmacist-led interventions. The study compares two groups: one receiving anticoagulation management using the MTM model, which includes medication review, personal medication records, action plans, interventions, referrals, and follow-up, and the other receiving standard care without these structured interventions. The MTM interventions occur at patient admission, during hospitalization, and after discharge to provide continuous medication management. Participants will be monitored from admission through six months after discharge. Researchers will assess medication errors related to anticoagulant therapy as the primary outcome, along with preventable, ameliorable, and potential adverse drug events. The study involves randomized assignment to groups and includes single masking. The total follow-up period for each participant is six months after hospital discharge to evaluate safety and efficacy outcomes comprehensively.

The Impact of MTM Model on the Efficacy and Safety of Anticoagulant Therapy in Postoperative Colorectal Cancer Patients